New analysis shows that revlimid® plus dexamethasone yielded a mean survival of 5.6 years for patients with multiple myeloma
June 22nd, 2008 by 
admin Celgene Corporation (NASDAQ: CELG) has declared that according to accumulation from a pooled think presented at the 13th dweller Hematology Association (EHA) congress in Copenhagen, Denmark, binary myeloma patients attractive REVLIMID® (lenalidomide) nonnegative Hexadrol significantly accumulated their activity rates.[1] A period model yielded an estimated stingy activity of 5.6 life-years with REVLIMID in compounding with Hexadrol (2. (Source: person / Oncology News From Medical News Today)
Posted in Cancer | 